In Silico Identification of Active Phytochemicals against COVID 19 by Targeting the SARS CoV 2 Spike Glycoprotein Through Molecular Docking: A Drug Repurposing Approach
The spread of coronavirus disease (COVID 19) has become one of the most significant pandemics in modern human history, affecting more than 70 million people worldwide. Currently, only a few fda approved drugs have suggested fighting the infection, in the absence of a specific antiviral treatment. Thus, repurposing the presently available drugs or using plant based bioactive compounds can be the fastest possible solution. In this study, the computational methodology of molecular docking techniques was performed to screen and identify the viable potent inhibitors against the SARS CoV 2 spike protein from a library of 200 active phytochemicals, based on their highest binding affinity towards the target protein. Later, the binding affinities of these phytochemicals were compared with that of the fda approved drug fluvoxamine, which is currently in use against the mild COVID 19 patients. Out of these, 86 phytochemicals that exhibited better binding energy of value 7.00kcal/mol, is selected for adme (absorption, distribution, metabolism, and excretion) analysis and drug likeliness studies to check the feasibility of these compounds. Wherein, 79 out of 86 phytochemicals showed a better theoretical affinity with sufficiently bearable adme properties. Thus, they can be the lead molecule for further investigation and validation processes towards developing natural inhibitors against the SARSCoV 2 virus. KeywordsNovel Coronavirus, Phytochemicals, SARSCoV 2, ADME, Drug likeliness, Molecular docking.